Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab

Trial Profile

Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2017

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Pembrolizumab (Primary) ; Valaciclovir (Primary)
  • Indications Breast cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms STOMP
  • Most Recent Events

    • 07 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 13 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.
    • 31 Mar 2017 Planned End Date changed from 1 Jul 2023 to 1 Nov 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top